Mergers & Acquisitions ·
Immuron engages LifeSci Capital as exclusive advisor to explore strategic initiatives
IMRNImmuron Ltd
Immuron Limited has engaged LifeSci Capital as its exclusive financial advisor to assist in the evaluation of strategic initiatives aimed at maximizing shareholder value. Potential actions under consideration include mergers, acquisitions, licensing arrangements, or other strategic transactions. The company stated there is no assurance that this process will result in any specific transaction and does not intend to provide updates unless a specific course of action is approved by its Board of Directors. Immuron Limited is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of infectious diseases.